In Brief Recent investigation suggested neuroprotective efficacy of a δ-opioid agonist in the brain. We investigated the effects of intrathecal treatment with a δ-opioid agonist (SNC80) on spinal cord ischemia (SCI) in rats. SCI was induced with an intraaortic balloon catheter. The animals were randomly allocated to one of the following five groups: 1) SNC80 before 9 min of SCI (SNC-9; n = 12), 2) vehicle before 9 min of SCI (V-9; n = 12), 3) SNC80 before 11 min of SCI (SNC-11; n = 10), 4) vehicle before 11 min of SCI (V-11; n = 12), or 5) sham (n = 12). SNC80 (400 nmol) or vehicle was administered 15 min before SCI. Forty-eight hours after reperfusion, hind-limb motor function was assessed by using the Basso, Beattie, Bresnahan (BBB) scale (0 = paraplegia; 21 = normal) and histological assessment of the L4 and L5 spinal segments was performed. BBB scores in the SNC-9 group were higher compared with those in the V-9 group (P < 0.05), whereas there were no differences in BBB scores between the SNC-11 and V-11 groups. There were significantly more normal neurons in the SNC-9 and SNC-11 groups than in the V-9 and V-11 groups (P < 0.05). The results indicate that intrathecal treatment with the δ-opioid agonist SNC80 can attenuate hind-limb motor dysfunction and neuronal injury after SCI in rats. IMPLICATIONS: Although recent evidence suggested neuroprotective efficacy of a δ-opioid agonist in the brain, there have been no data regarding its efficacy in the spinal cord. The results in this study showed that the δ-opioid agonist SNC80 attenuated neuronal injury after spinal cord ischemia in rats. Toshinori Horiuchi, Masahiko Kawaguchi, Takanori Sakamoto, Naoko Kurita, Satoki Inoue, Mitsutoshi Nakamura, Noboru Konishi, and Hitoshi Furuya
No takes yet. Share an insight, caveat, or question.
Horiuchi et al. (2004) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: